Trump's surgeon general pick criticizes others' conflicts but profits from wellness product sales

Scientists are exploring whether mRNA technology—the same breakthrough used in COVID-19 vaccines—could be repurposed to help the body fight off HIV. Early research suggests it might train the immune system to target and eliminate the virus, offering a potential new path toward a cure or long-term treatment.

Editor’s Note: HIV has been one of medicine’s toughest challenges, with no cure yet. If mRNA can crack this puzzle, it could be a game-changer—not just for HIV but for how we tackle other stubborn viruses. It’s still early, but the idea that COVID-era science might unlock solutions for another global health crisis is pretty exciting.

A supplement once popular mainly with male bodybuilders is now being heavily marketed to women, touted as a miracle solution for antiaging, toning, and overall wellness. But here’s the catch—it’s not a magic pill. You still have to put in the work at the gym.

Editor’s Note: This story highlights how marketing trends shift to tap into new demographics—in this case, women seeking quick fixes for fitness and aging. While the supplement’s growing appeal shows changing consumer habits, the underlying message is a reminder that no product replaces effort. It’s also a peek into how industries rebrand old products for fresh audiences, sometimes blurring the line between hope and reality.

Elon Musk recently addressed reports about his ketamine use, clarifying that while he's used it therapeutically in the past, he denies frequent or recreational use. The discussion resurfaced amid broader debates about ketamine’s medical applications versus its potential for misuse.

Editor’s Note: Musk’s comments throw a spotlight on ketamine’s dual reputation—as a promising treatment for depression and PTSD, but also a drug with abuse risks. His high-profile admission keeps the conversation going about how society views mental health treatments, celebrity transparency, and the fine line between medicine and recreation.

A Michigan woman with sickle cell disease is sounding the alarm after the CDC quietly disbanded its team researching safe birth control options for chronic conditions. She believes this decision could literally put her life—and others like her—in danger. Public health experts are worried too, saying doctors may now lack crucial guidance, leaving vulnerable women without proper care.

Editor’s Note: This isn't just bureaucratic shuffling—real lives are on the line. Sickle cell disease already complicates pregnancy and birth control choices, and without specialized research, doctors are left guessing. It’s a stark reminder of how policy shifts can ripple through people’s lives in deeply personal, even dangerous, ways.

Jillian Sackler, a philanthropist and staunch defender of her late husband Arthur Sackler’s reputation, has passed away at 84. While the Sackler name became controversial due to Purdue Pharma’s role in the opioid crisis, she argued that Arthur—who died before the scandal—shouldn’t be lumped in with the fallout. Jillian was also recognized for her work bridging U.S.-China relations, like when the China Institute honored her in 2018.

Editor’s Note: This isn’t just another obituary—it’s a nuanced look at how legacies get tangled in public perception. Jillian Sackler’s life reflects the messy intersection of philanthropy, family reputation, and corporate scandal. Even as the Sackler name became shorthand for the opioid crisis, her story reminds us that individuals within families (or companies) can have vastly different roles and impacts. Plus, her diplomatic work adds another layer to a complicated narrative about influence and accountability.